Onychomycosis Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Onychomycosis Epidemiology Forecast Report Coverage

Expert Market Research's “Onychomycosis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of onychomycosis. It projects the future incidence and prevalence rates of onychomycosis cases across various onychomycosis populations. The study covers age, gender, and type as major determinants of the population. The report highlights patterns in the prevalence of onychomycosis over time and projects future trends based on multiple variables.

Onychomycosis Understanding: Disease Overview

Onychomycosis is a chronic fungal nail infection caused primarily by dermatophytes, leading to nail discoloration, thickening, and onycholysis, with higher prevalence in older adults and immunocompromised individuals. The condition, commonly referred to as tinea unguium, often begins in toenails and progresses slowly if untreated. Epidemiological trends indicate an increasing global burden due to aging populations, diabetes prevalence, and lifestyle factors. Disease management typically requires prolonged antifungal therapy, and recurrence is common.

Key Report Insights

Onychomycosis Epidemiology Perspective

The onychomycosis epidemiology report provides comprehensive insights into the historical, current, and forecasted patient population trends across the regional markets. Expert Market Research provides both current and forecast trends for the onychomycosis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for onychomycosis and its trends. The onychomycosis detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Type-Specific Disease Burden and Epidemiology Analysis by Region

Read more about this report - Request a Free Sample

Country-wise Onychomycosis Epidemiology

The onychomycosis epidemiology data and findings for the region-specific countries are also provided in the epidemiology section.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Onychomycosis Epidemiology Landscape

• Key Market Gaps

Onychomycosis shows clear diagnostic distortion, with community prevalence (8.57%) far lower than hospital detection (24.19%), indicating underdiagnosis in primary care. Combined with 6-12 months treatment duration and 20-25% recurrence rates, this creates a cycle of incomplete clearance and repeated infections.

• Untapped Opportunities

This diagnostic gap highlights strong unmet need for earlier and more accurate detection, where PCR methods (85-95% sensitivity) significantly outperform conventional KOH/culture (50-70%). Improved point-of-care testing and adherence-focused treatment models can reduce delayed diagnosis and unnecessary prolonged antifungal exposure.

• Emerging Growth Areas

High recurrence (20-53%) and poor nail penetration of existing therapies are driving innovation in nanotechnology-based and sustained-release antifungal systems. With prevalence ranging from 2%-8% globally and up to 22.9% in tested populations, focus is shifting toward durable mycological cure rather than temporary symptom control.

Onychomycosis: Treatment Overview

Onychomycosis treatment primarily involves prolonged topical or systemic antifungal therapy due to slow nail plate penetration and high recurrence rates. Standard regimens often require extended use and show variable complete cure outcomes, especially in chronic infections. A Phase 2 interventional pipeline study (NCT07382427) is actively evaluating a novel topical terbinafine-based formulation designed to improve drug delivery into the nail bed and enhance antifungal efficacy against dermatophytes, with endpoints focused on clinical and mycological cure rates. Patients with dermatophyte onychomycosis frequently need combined pharmacologic and debridement-based approaches, reflecting ongoing unmet need for faster, more durable treatment options.

Key Questions Answered

• What is the current and projected burden of onychomycosis across 8 major markets?
• Which countries across 8 major markets account for the highest onychomycosis patient populations and fastest growth rates?
• What is the diagnosed versus undiagnosed patient population of onychomycosis across key countries in 8 major markets?
• Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of onychomycosis across 8 major markets?
• What are the major drivers contributing to the increasing burden of onychomycosis across 8 major markets?
• How do major comorbidities and risk factors influence onychomycosis epidemiology trends across 8 major markets?
• What are the regional trends in advanced disease progression, treatment uptake, and patient management of onychomycosis across 8 major markets?
• Which patient segments represent the highest unmet clinical need in the onychomycosis landscape across 8 major markets?
• Which therapeutic areas linked to onychomycosis are expected to witness the strongest growth opportunities across 8 major markets?
• How is the onychomycosis epidemiology landscape expected to evolve over the next 5 to 10 years across 8 major markets?
• Which countries across 8 major markets offer the most attractive market opportunities based on onychomycosis epidemiology and healthcare infrastructure?
• Which epidemiological trends are expected to influence future drug development and market access strategies for onychomycosis across 8 major markets?

Scope of the Onychomycosis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of onychomycosis based on several factors.
• The Onychomycosis Epidemiology Forecast Report covers data for the major markets.
• The onychomycosis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Onychomycosis Market

Onychomycosis Pipeline Analysis Report